Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) – Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 – 2020

“Rise in incidence of diabetes across the globe has elevated the need of innovative diabetic management devices which in turn has increased adoption of continuous glucose monitoring (CGM) devices. The existing glucose monitoring devices have few gaps which are bridged by the innovative CGM. With continuous glucose monitoring, significant improvement has been observed in stabilizing elevated A1C levels which in turn reduces risk of developing long term diabetic complications. Other driving factors for CGM market are technological innovation in the form of artificial pancreas, increasing awareness among developed, developing and under developed economies, and rise in incidences of diabetic patients. However, factors such as strict regulatory impositions, inadequate reimbursement options for CGM and accuracy as well as cost of the CGMs are restraining the market growth.

The global continuous glucose monitors market generated revenue of $194.8 million in 2012 and is expected to reach market size of value $568.5 million by 2020 growing at a CAGR of 14.8% during 2013-2020. This growth is attributed to increase in technological innovations namely launch of artificial pancreas, convenience offered by CGM over self monitoring glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM.

Segment Analysis

Among the product category market, insulin pump market is expected to witness highest growth rate followed by glucose sensors market. Driver for insulin pump market is majorly integration of insulin pumps with the CGMs which is necessary for closing the loop algorithm. Furthermore, glucose sensors market is projected to generate highest revenue mainly as they have to be replaced after every 3 to 7 days time and each sensor cost is a significant addition in the overall market.

Global CGM market is segmented on the basis of application as home settings, Diagnostics and Hospitals. Among all the application segments home settings is expected to generate maximum revenue by 2020.

North America is the maximum revenue generating segment across the globe mainly due to rapid acceptance of innovative technology, well penetrated reimbursement system when compared with other geographies and rise in patient pool. Asia Pacific is expected to grow at a faster rate due to high patient pool, geographical expansion of market players, increase in income levels and living standards of the people.

Key market players in this market includes, Medtronics, Dexcom, Animas Corporation, Ypsomed AG, Omnipod and Miraculins, Inc inlcuding others. The major strategy adopted the market players across this geography is Collaborations, Product launches and approvals. Collaborations specifically focus on distribution and commercialization of the devices.

Key Benefits of the Report

The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more
Market is forecasted for period of seven years 2013 to 2020 with market revenues for 2 historic years of 20110and 2012
Identification and analysis of key pockets of investment for CGM manufacturers
Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market
Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario
The report identifies and profiles key market participants that would drive innovation in the CGM market”

“1   Introduction     1.1     Objectives and Scope

1.2     Report Description

1.3     Key Benefits of the Report

1.4     Research Methodology

  2     Executive Summary

  3     Global Continuous Glucose Monitors Market Overview

3.1     Healthcare Expenditure on Diabetes Worldwide

3.2     Type-1 Diabetics to Remain Key Target for CGM Market

3.2.1  Type-1 Diabetes

3.2.1.1         Type-1 Diabetes in Young People

3.2.2  Type-2 Diabetes

3.2.2.1         Type-2 Diabetes in Young People

3.2.3  Gestational Diabetes

3.2.4  Other Types of Diabetes

3.3     Market Intelligence

3.3.1  Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020

3.3.1.1         Fda Approval of Artificial Pancreas

3.3.1.2         Convenience Offered by CGM Over Self Monitoring Glucose Devices

3.3.1.3         Rise in Incidences of Diabetes Cases Globally

3.3.1.4         Earlier Detection of the Hypo and Hyperglycemic Events by CGM

3.3.1.5         Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption

3.3.1.6         Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM

3.3.1.7         Strict Regulatory Impositions

3.3.1.8         Increase in Awareness Among Developing and Underdeveloped Economies

3.3.2  Top Three Winning Strategies in the Continuous Glucose Monitors Market

3.3.2.1         Global Market Players Positioning

3.3.3  Top Investment Pockets in Continuous Glucose Monitors Market

3.3.3.1         Continuous Glucose Monitors Market – by Device

3.3.3.2         Continuous Glucose Monitors Market – by Applications

3.3.3.3         Continuous Glucose Monitors Market – by Geography

3.4     Regulations

3.5     Reimbursement Scenario

3.6     Market Dynamics

3.6.1  Drivers

3.6.1.1         Convenience Offered by CGM Over Self Monitoring Glucose Devices

3.6.1.2         FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System

3.6.1.3         Earlier Detection of the Hypo and Hyperglycemic Events by CGM

3.6.1.4         Rise in Incidences of Diabetes Cases Globally

3.6.1.5         Increase in Awareness Among the Population in Developing and Underdeveloped Economies

3.6.2  Restraints

3.6.2.1         Strict Regulatory Impositions

3.6.2.2         Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption

3.6.2.3         Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM

3.6.3  Market Opportunity

3.6.3.1         Growth in Emerging Market

3.6.4  Winning Strategies for Mncs in Emerging Markets

3.6.4.1         Tailoring the Existing Products to the Local Market Needs

3.6.4.2         Adoption of a Proactive Hybrid Model Rather Than Distributor Management

3.6.4.3         Service Rendered Makes a Difference

3.6.4.4         Partnership and Acquisition Key to Enhance Reach and Market Position

3.6.4.5         Adopting An Emerging-Market Attitude

  4     Continuous Glucose Monitoring Systems Market – by Devices

4.1     Transmitter and Receivers

4.2     Sensors

4.2.1  Market Trend

4.2.1.1         Non-Invasive Glucose Sensors

4.2.1.2         Subcutaneous Sensors (Minimally Invasive Sensors)

4.2.1.3         Conventional Technology – Holter-Type Retrospective Sensors

4.2.1.4         Advanced Technology – Real-Time Sensors

4.3     Insulin Pump

4.3.1  Advantages of Insulin Pump

4.3.2  Disadvantages of Insulin Pump

4.3.3  Market Trend

  5     Continuous Glucose Monitoring System Market – by Application

5.1     Diagnostics/Clinics

5.2     Hospitals

5.3     Home Settings

5.4     Role of CGM in Private Practice

5.4.1  Team Members

5.4.2  Clinical Space

5.4.3  Scheduling

5.4.4  Keeping the Patients Informed

  6     Continuous Glucose Monitoring System Market – by Age

6.1     Children and Teens

6.2     Youth

6.3     Middle Elderly and Aged

  7     CGM Systems Market by Geography

7.1     North America

7.2     Europe

7.2.1  Financial Cost Incurred

7.3     Asia Pacific

7.4     Row

  8     Company Profiles

8.1     Medtronic Inc.

8.1.1  Company Overview

8.1.2  Company Snapshot

8.1.3  Business Performance

8.1.4  Strategic Moves and Developments

8.1.4.1         Principal Strategies: Product Launch

8.1.4.2         Secondary Strategies: Approval

8.1.4.3         Other Strategies: Collaboration

8.1.5  SWOT Analysis & Strategic Conclusions

8.2     Dexcom Inc.

8.2.1  Company Overview

8.2.2  Company Snapshot

8.2.3  Business Performance

8.2.4  Strategic Moves and Developments

8.2.4.1         Principal Strategies: Agreement/Partnership

8.2.4.2         Secondary Strategies: Acquisition

8.2.5  SWOT Analysis & Strategic Conclusions

8.3     Novo Nordisk

8.3.1  Company Profile

8.3.2  Company Snapshot

8.3.3  Strategic Moves and Developments

8.3.4  SWOT Analysis & Strategic Conclusions

8.4     Spring Health Solution Ltd

8.4.1  Company Profile

8.4.2  Company Snapshot

8.4.3  Strategic Moves and Developments

8.4.3.1         Principal Strategies

8.4.4  SWOT Analysis & Strategic Conclusions

8.5     Roche

8.5.1  Company Profile

8.5.2  Company Snapshot

8.5.3  Strategic Moves and Developments

8.5.4  SWOT Analysis & Strategic Conclusions

8.6     Animas Corporation

8.6.1  Company Profile

8.6.2  Company Snapshot

8.6.3  Strategic Moves and Developments

8.6.3.1         Principal Strategies

8.6.4  SWOT Analysis & Strategic Conclusions

8.7     Ypsomed AG

8.7.1  Company Profile

8.7.2  Company Snapshot

8.7.3  Strategic Moves and Developments

8.7.3.1         Principal Strategies: Product Expansion

8.7.3.2         Secondary Strategies: New Subsidiary

8.7.3.3         Other Strategies: Acquisition and Agreements

8.7.4  SWOT Analysis & Strategic Conclusions

8.8     Insulet Corporation

8.8.1  Company Profile

8.8.2  Company Snapshot

8.8.3  Strategic Moves and Developments

8.8.3.1         Principal Strategies

8.8.4  SWOT Analysis & Strategic Conclusions”

“Table 1            Features of Currently Available Stand-Alone CGM Systems (as of March 2013)

Table 2            Features of Currently Available Integrated CGM Systems (as of March 2013)

Table 3            Global Continuous Glucose Monitoring Systems Market by Product Category, 2011-2020, ($Million)

Table 4            Global CGM Transmitters And Receivers Market by Geography, 2011 – 2020, ($Million)

Table 5            Global CGM Sensors Market by Geography, 2011 – 2020, ($Million)

Table 6            Global CGM Insulin Pump Market by Geography, 2011 – 2020, ($Million)

Table 7            Global CGM Market by Application Segments, 2011 – 2020, ($Million)

Table 8            Global CGM Market in Diagnostic Centers, by Geography, 2011 – 2020, ($Thousand)

Table 9            Global CGM Market in Hospitals, by Geography, 2011 – 2020, ($Thousand)

Table 10          Global CGM Market in Home Settings, by Geography, 2011 – 2020, ($Million)

Table 11          Global CGM Market by Age, 2011 – 2020, ($Million)

Table 12          Type-1 Diabetes (0-14 Years), 2013

Table 13          Factors Impacting Geographical Regions in 2013 And 2020

Table 14          Global Continuous Glucose Monitoring Systems by Geography, 2011 – 2020, ($Million)

Table 15          The Prevalence of Diabetes in the Adult Population Across the U.K. in 2011

Table 16          Prevalence Estimates of Diabetes (20-79 Years), 2013, Europe

Table 17          Prevalence Estimates of Diabetes, 2013 & 2035

Table 18          Prevalence Estimates of Diabetes (20-79 Years), 2013, Africa Region

Table 19          Medtronic Business Snapshot

Table 20          Dexcom Inc. Business Snapshot

Table 21          Nova Nordisk Business Snapshot

Table 22          Spring Health Solution Ltd Business Snapshot

Table 23          Roche Business Snapshot

Table 24          Animas Corporation Business Snapshot

Table 25          Ypsomed AG Business Snapshot

Table 26          Insulet Corporation Business Snapshot

“

“Figure 1  Global Health Expenditure due to Diabetes, by Geography ($Billion)

Figure 2           Global Health Expenditure due to Diabetes, 20-79 Years ($Billion)

Figure 3           Treatment of Diabetes, 2011

Figure 4           Similarities in Cause of Pre-Diabetes and Type-2 Diabetes

Figure 5           CGM Adoption by Different Types of Diabetes Patients

Figure 6           Prevalence of Type-1 Diabetes, by Geography, (Thousand)

Figure 7           Global Prevalence of Type-2 Diabetes in 2000 & Estimated Prevalence in 2030

Figure 8           Top Factors Impacting CGM Market, 2013-2020

Figure 9           Top Winning Strategy in CGM Market, 2010 To 2013 (September)

Figure 10         Top Winning Strategy in CGM Market by Year

Figure 11         Global Market Players Positioning

Figure 12         Top Investment Pockets in CGM Device Markets

Figure 13         Top Investment Pockets in CGM Application Markets

Figure 14         Top Investment Pockets in CGM Geography Markets

Figure 15         Number of Incidences of Diabetes Globally, by Geography (2000, 2011 & 2030)

Figure 16         GDP Per Capita in Emerging Economies

Figure 17         Emerging Market Capitalization Strategies

Figure 18         Global CGM Market among Children, 2011-2020, ($Million)

Figure 19         Global CGM Market among Teens, 2011-2020, ($Million)

Figure 20         Global CGM Market among Youth, 2011-2020, ($Million)

Figure 21         Global CGM Market among Middle Elderly, 2011-2020, ($Million)

Figure 22         Global CGM Market among Aged, 2011-2020, ($Million)

Figure 23         North America CGM Market, 2013-2020, ($Million)

Figure 24         Cases of Diabetes by Ages in NAC (1000s) (2013 E)

Figure 25         Europe CGM Market, 2013-2020, ($Million)

Figure 26         Cases of Diabetes by Ages in Europe (1000s) (2013 E)

Figure 27         Asia Pacific CGM Market, 2013-2020, ($Million)

Figure 28         Top 10 Countries with Diabetes Incidences 2013 and 2035

Figure 29         Row CGM Market, 2013-2020, ($Million)

Figure 30         Financial Revenues by Business Units (2013)

Figure 31         Financial Revenues by Geography (2013)

Figure 32         Financial Revenues by Geography (2012)”